Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.
Also called NCT03156842
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 138 participants
- Registry
-
NCT03156842
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03156842. Randomized; triple masking; primary purpose treatment. Start 2017-05-29 (actual); primary completion 2018-12-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
- Acronym
- FIRST
- Condition
- Essential Hypertension
- Condition
- Dyslipidemia
- Intervention (Drug)
- Fimasartan/Amlodipine, Rosuvastatin
- Intervention (Drug)
- Fimasartan/Amlodipine
- Intervention (Drug)
- Fimasartan, Rosuvastatin
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct03156842- Content hash
2e7b1aa5b0cb3a5a0d2bfb9c38c55eb6b591cf69a9c3dd58f4526207fd4adb18